SYRE

Announcements

Nothing here yet

Daily updates

• SPY072 Phase 2 results were statistically significant but fell short of RA monotherapy benchmarksAug 26, 2026

FDA designations

Nothing here yet

News

• Spyre Therapeutics announced the launch of the SPY772 program and initiated the Phase 2 SKYLIGHT trial in hidradenitis suppurativaAug 10, 2026
• Spyre reported promising induction results from Part A of the SKYLINE trial evaluating SPY002 in moderate-to-severe ulcerative colitisJun 15, 2026
• Spyre Therapeutics completed enrollment in the SKYWAY basket trial of SPY072Jun 3, 2026
• Spyre reported promising induction results for SPY001 in Phase 2 SKYLINE trial for ulcerative colitisApr 13, 2026
• Spyre Therapeutics announces positive interim Phase 1 results for SPY003, its novel, half-life extended anti-IL-23 antibodyNov 5, 2025